Core Viewpoint - Jiren Pharmaceutical is shifting its IPO target to the Beijing Stock Exchange after failing in the A-share market, facing multiple challenges including high accounts receivable and inventory, declining gross margins, and governance issues due to family control [2]. Financial Performance - Jiren Pharmaceutical's revenue is projected to grow from approximately 1.024 billion yuan in 2022 to 1.23 billion yuan in 2024, but net profit is declining, with figures of 157 million yuan in 2022 dropping to 131 million yuan in both 2023 and 2024 [3]. - In the first half of 2025, revenue fell to 563 million yuan and net profit to 55 million yuan, showing significant declines compared to the same period in 2024 [3]. Cash Flow and Working Capital - The company's net cash flow from operating activities has been volatile and consistently lower than net profit, with figures dropping from 156 million yuan in 2022 to just 10 million yuan in 2024 [4]. - As of the end of 2024, accounts receivable reached 796 million yuan, accounting for 45.43% of total assets, while inventory was 267 million yuan, making up 15.24% of total assets [4]. Gross Margin Trends - Jiren Pharmaceutical's gross margin has been declining, from 51.3% in 2022 to 41.71% in 2024, with a further drop to 41.05% in the first half of 2025, indicating weakened profitability [5]. - The decline in gross margin is attributed to fluctuations in raw material prices and changes in product sales structure, with key raw materials experiencing significant price increases [5]. Product Performance and Market Challenges - The core product, Shufeng Jiedu Capsule, has seen a decline in sales from 503 million yuan in 2022 to 136 million yuan in the first half of 2025, with a 25% drop in 2024 compared to 2022 [6]. - The company is attempting to increase market share through price reductions, but the effectiveness of this strategy remains uncertain [6]. Governance and Ownership Structure - Jiren Pharmaceutical is heavily controlled by the founding family, with the controlling shareholder holding 87.06% of the shares, raising concerns about governance and decision-making transparency [9]. - The family’s involvement in management and the company's stock incentive plans reflect a governance model that may lack checks and balances, potentially affecting minority shareholders' rights [13]. Dividend Policy - Despite financial pressures, Jiren Pharmaceutical has maintained cash dividends, distributing 20 million yuan in 2021, 23 million yuan in 2022, and 25 million yuan in 2023, raising questions about the rationality of cash distribution amid declining performance [13].
济人药业转战北交所 迎盈利与治理双重考
凤凰网财经·2026-01-03 12:37